From: gts (gts_2000@yahoo.com)
Date: Sun Feb 16 2003 - 07:49:15 MST
Whatever, Rafal. As I was saying, it is clear that your ego is firmly
entrenched in your self-prescribed role as nay-sayer on this subject.
The FDA has a less progressive attitude than you, my friend, and I am no
fan of the FDA.
Below is yet *another* positive research finding concerning selegiline
(deprenyl). In this double blind controlled study, selegiline was found
to improve verbal memory in Alzheimer's patients (we've been discussing
Parkinson's here, mostly, but selegiline (deprenyl) has also been found
useful in Alzheimer's).
Concerning this report below of enhanced verbal memory from selegiline
(deprenyl), this is probably a good time for me to mention the most
surprising and unusual benefit that I *personally* have experienced from
this drug:
Immediately, literally on the day of my first 1 mg dose, I noticed a
dramatic improvement in my ability to understand the lyrics in music.
Lyrics that had previously been lost in the loud background
instrumentals suddenly became discernible to me. Popular tunes that I
had heard and enjoyed literally hundreds of times over the years on the
radio, but without understanding most of the lyrics, suddenly made
lyrical sense to me. Moreover my general appreciation of music improved
along with my ability to understand the lyrics. This increased ability
to appreciate lyrical music was entirely surprising to me. I would guess
that this positive effect is related to the enhancement of verbal memory
as seen in these Alzheimer's patients:
ABSTRACT:
L-deprenyl therapy improves verbal memory
in amnesic Alzheimer patients.
Finali G, Piccirilli M, Oliani C, Piccinin GL.
Department of Neurology, Perugia University, Italy.
Clin Neuropharmacol 1991 Dec;14(6):523-36
ABSTRACT
Altered monoaminergic neurotransmission could play an important role in
the cognitive dysfunctions typical of dementia of the Alzheimer type
(DAT). DAT is not, however, a homogenous phenomenon inasmuch as two
forms are distinguishable: early onset (EO) and late onset (LO).
Moreover, focal patterns of neuropsychological deterioration fall into
various subgroups. According to our hypothesis, DAT patients, who at the
onset of the disease mainly manifest memory disorders, also represent a
specific subgroup characterized by impaired cortically projecting
catecholaminergic pathways. In a 6-month randomized, double-blind,
cross-over study versus placebo we analysed the influence of L-deprenyl
on the verbal memory of 19 amnesic EO-DAT patients. Verbal memory was
assessed by means of the Rey Auditory Verbal Learning Test. The results
obtained show significantly better performances for L-deprenyl treated
patients in learning and long-term memory skills. We suggest that
L-deprenyl, through selective inhibition of MAO-B and by increasing the
activity of the catecholaminergic systems, positively influences
cognitive functions and behaviour founded on memory efficiency.
This archive was generated by hypermail 2.1.5 : Sun Feb 16 2003 - 07:50:44 MST